Envestnet Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Envestnet Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$681K	Buy	+7,666	New	+$559K	﹤0.01%	3875

Other funds holding SYRE

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

FMI

F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Envestnet Asset Management's SYRE Position: Q2 2026 in Review

Envestnet Asset Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 7,666 shares worth $681K. The stake represents ﹤0.01% of the portfolio and ranks #3875 among its holdings.

50 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Envestnet Asset Management held 7,666 shares of Spyre Therapeutics worth $681K as of Q2 2026.
Spyre Therapeutics was a new Envestnet Asset Management position in Q2 2026.
Spyre Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3875 holding.
50 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.